Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Ghrelin, peptide YY and their receptors: gene expression in brain from subjects with and without Prader-Willi syndrome.

Talebizadeh Z, Kibiryeva N, Bittel DC, Butler MG.

Int J Mol Med. 2005 Apr;15(4):707-11.

2.

Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome.

Goldstone AP, Holland AJ, Butler JV, Whittington JE.

Int J Obes (Lond). 2012 Dec;36(12):1564-70. doi: 10.1038/ijo.2011.274. Epub 2012 Jan 24.

PMID:
22270375
3.

Plasma peptide YY and ghrelin levels in infants and children with Prader-Willi syndrome.

Butler MG, Bittel DC, Talebizadeh Z.

J Pediatr Endocrinol Metab. 2004 Sep;17(9):1177-84.

4.

Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children.

Bizzarri C, Rigamonti AE, Luce A, Cappa M, Cella SG, Berini J, Sartorio A, Müller EE, Salvatoni A.

Eur J Endocrinol. 2010 Mar;162(3):499-505. doi: 10.1530/EJE-09-1033. Epub 2009 Dec 17.

5.

Peptide YY, cholecystokinin, insulin and ghrelin response to meal did not change, but mean serum levels of insulin is reduced in children with Prader-Willi syndrome.

Paik KH, Jin DK, Lee KH, Armstrong L, Lee JE, Oh YJ, Kim S, Kwon EK, Choe YH.

J Korean Med Sci. 2007 Jun;22(3):436-41.

6.

In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels.

Purtell L, Sze L, Loughnan G, Smith E, Herzog H, Sainsbury A, Steinbeck K, Campbell LV, Viardot A.

Neuropeptides. 2011 Aug;45(4):301-7. doi: 10.1016/j.npep.2011.06.001. Epub 2011 Jul 1.

PMID:
21722955
7.

Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome.

Tan TM, Vanderpump M, Khoo B, Patterson M, Ghatei MA, Goldstone AP.

J Clin Endocrinol Metab. 2004 Aug;89(8):4162-5.

PMID:
15292365
8.

A lesser postprandial suppression of plasma ghrelin in Prader-Willi syndrome is associated with low fasting and a blunted postprandial PYY response.

Giménez-Palop O, Giménez-Pérez G, Mauricio D, González-Clemente JM, Potau N, Berlanga E, Trallero R, Laferrère B, Caixàs A.

Clin Endocrinol (Oxf). 2007 Feb;66(2):198-204.

PMID:
17223988
9.

Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.

Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, Sainsbury A, Steinbeck K, Campbell LV, Viardot A.

J Clin Endocrinol Metab. 2011 Aug;96(8):E1314-9. doi: 10.1210/jc.2011-0038. Epub 2011 Jun 1.

PMID:
21632815
10.

Abnormal response to the anorexic effect of GHS-R inhibitors and exenatide in male Snord116 deletion mouse model for Prader-Willi syndrome.

Lin D, Wang Q, Ran H, Liu K, Wang Y, Wang J, Liu Y, Chen R, Sun Y, Liu R, Ding F.

Endocrinology. 2014 Jul;155(7):2355-62. doi: 10.1210/en.2013-2083. Epub 2014 Apr 15.

PMID:
24735326
11.

Macronutrient Regulation of Ghrelin and Peptide YY in Pediatric Obesity and Prader-Willi Syndrome.

Gumus Balikcioglu P, Balikcioglu M, Muehlbauer MJ, Purnell JQ, Broadhurst D, Freemark M, Haqq AM.

J Clin Endocrinol Metab. 2015 Oct;100(10):3822-31. doi: 10.1210/jc.2015-2503. Epub 2015 Aug 10.

12.

Maintenance of a normal meal-induced decrease in plasma ghrelin levels in children with Prader-Willi syndrome.

Bizzarri C, Rigamonti AE, Giannone G, Berardinelli R, Cella SG, Cappa M, Müller EE.

Horm Metab Res. 2004 Mar;36(3):164-9.

PMID:
15057669
13.

Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma.

Goldstone AP, Patterson M, Kalingag N, Ghatei MA, Brynes AE, Bloom SR, Grossman AB, Korbonits M.

J Clin Endocrinol Metab. 2005 May;90(5):2681-90. Epub 2005 Feb 1.

PMID:
15687345
14.

Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome.

Kuppens RJ, Diène G, Bakker NE, Molinas C, Faye S, Nicolino M, Bernoux D, Delhanty PJ, van der Lely AJ, Allas S, Julien M, Delale T, Tauber M, Hokken-Koelega AC.

Endocrine. 2015 Dec;50(3):633-42. doi: 10.1007/s12020-015-0614-x. Epub 2015 May 20.

16.

Plasma obestatin and ghrelin levels in subjects with Prader-Willi syndrome.

Butler MG, Bittel DC.

Am J Med Genet A. 2007 Mar 1;143A(5):415-21.

17.

Metabolic profiling in Prader-Willi syndrome and nonsyndromic obesity: sex differences and the role of growth hormone.

Irizarry KA, Bain J, Butler MG, Ilkayeva O, Muehlbauer M, Haqq AM, Freemark M.

Clin Endocrinol (Oxf). 2015 Dec;83(6):797-805. doi: 10.1111/cen.12766. Epub 2015 Apr 1.

18.

High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome.

DelParigi A, Tschöp M, Heiman ML, Salbe AD, Vozarova B, Sell SM, Bunt JC, Tataranni PA.

J Clin Endocrinol Metab. 2002 Dec;87(12):5461-4.

PMID:
12466337
19.

Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.

De Waele K, Ishkanian SL, Bogarin R, Miranda CA, Ghatei MA, Bloom SR, Pacaud D, Chanoine JP.

Eur J Endocrinol. 2008 Oct;159(4):381-8. doi: 10.1530/EJE-08-0462. Epub 2008 Jul 4.

20.

Prader-Willi syndrome as a model of human hyperphagia.

Tauber M, Diene G, Mimoun E, Çabal-Berthoumieu S, Mantoulan C, Molinas C, Muscatelli F, Salles JP.

Front Horm Res. 2014;42:93-106. doi: 10.1159/000358317. Epub 2014 Apr 7. Review.

PMID:
24732928

Supplemental Content

Support Center